Early versus late parenteral nutrition in ICU patients: cost analysis of the EPaNIC trial

Simon Vanderheyden, Michael P Casaer, Katrien Kesteloot, Steven Simoens, Thomas De Rijdt, Guido Peers, Pieter J Wouters, Jocelijn Coenegrachts, Tine Grieten, Katleen Polders, Ann Maes, Alexander Wilmer, Jasperina Dubois, Greet Van den Berghe, Dieter Mesotten, Simon Vanderheyden, Michael P Casaer, Katrien Kesteloot, Steven Simoens, Thomas De Rijdt, Guido Peers, Pieter J Wouters, Jocelijn Coenegrachts, Tine Grieten, Katleen Polders, Ann Maes, Alexander Wilmer, Jasperina Dubois, Greet Van den Berghe, Dieter Mesotten

Abstract

Introduction: The EPaNIC randomized controlled multicentre trial showed that postponing initiation of parenteral nutrition (PN) in ICU-patients to beyond the first week (Late-PN) enhanced recovery, as compared with Early-PN. This was mediated by fewer infections, accelerated recovery from organ failure and reduced duration of hospitalization. Now, the trial's preplanned cost analysis (N = 4640) from the Belgian healthcare payers' perspective is reported.

Methods: Cost data were retrieved from individual patient invoices. Undiscounted total healthcare costs were calculated for the index hospital stay. A cost tree based on acquisition of new infections and on prolonged length-of-stay was constructed. Contribution of 8 cost categories to total hospitalization costs was analyzed. The origin of drug costs was clarified in detail through the Anatomical Therapeutic Chemical (ATC) classification system. The potential impact of Early-PN on total hospitalization costs in other healthcare systems was explored in a sensitivity analysis.

Results: ICU-patients developing new infection (24.4%) were responsible for 42.7% of total costs, while ICU-patients staying beyond one week (24.3%) accounted for 43.3% of total costs. Pharmacy-related costs represented 30% of total hospitalization costs and were increased by Early-PN (+608.00 EUR/patient, p = 0.01). Notably, costs for ATC-J (anti-infective agents) (+227.00 EUR/patient, p = 0.02) and ATC-B (comprising PN) (+220.00 EUR/patient, p = 0.006) drugs were increased by Early-PN. Sensitivity analysis revealed a mean total cost increase of 1,210.00 EUR/patient (p = 0.02) by Early-PN, when incorporating the full PN costs.

Conclusions: The increased costs by Early-PN were mainly pharmacy-related and explained by higher expenditures for PN and anti-infective agents. The use of Early-PN in critically ill patients can thus not be recommended for both clinical (no benefit) and cost-related reasons.

Trial registration: ClinicalTrials.gov NCT00512122.

Figures

Figure 1
Figure 1
Cost tree (cost allocation in the form of a decision tree). Costs are allocated by studied randomly assigned treatment (first branch), by the acquisition of a new infection (second branch), and by prolonged intensive care unit (ICU) stay, defined as an ICU stay beyond 8 days (third branch). The percentages represent the proportion of patients for the entire study population in each branch. The costs in euros (EUR) represent the total costs for all patients in each branch and - between brackets - mean cost per patient. Costs reported in euros are rounded at zero decimals. Early PN, parenteral nutrition administered during the first week of critical illness when enteral nutrition is insufficient; Late PN, no parenteral nutrition administered before day 8 of critical illness.
Figure 2
Figure 2
Pareto chart of the costs for the total EPaNIC trial population. The histogram depicts the relative size of each cost category in comparison with the total cost. The line graph shows their cumulative contribution. Important cost drivers for total hospital stay in the EPaNIC trial population are highlighted. EPaNIC, Impact of Early Parenteral Nutrition completing enteral nutrition In Critical illness; PD, per diem.

References

    1. Dhaliwal R, Jurewitsch B, Harrietha D, Heyland DK. Combination enteral and parenteral nutrition in critically ill patients: harmful or beneficial? A systematic review of the evidence. Intensive Care Med. 2004;30:1666–1671.
    1. Bauer P, Charpentier C, Bouchet C, Nace L, Raffy F, Gaconnet N. Parenteral with enteral nutrition in the critically ill. Intensive Care Med. 2000;26:893–900. doi: 10.1007/s001340051278.
    1. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Van den Berghe G. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365:506–517. doi: 10.1056/NEJMoa1102662.
    1. Blackburn GL, Wollner S, Bistrian BR. Nutrition support in the intensive care unit: an evolving science. Arch Surg. 2010;145:533–538. doi: 10.1001/archsurg.2010.97.
    1. Darmon P, Lochs H, Pichard C. Economic impact and quality of life as endpoints of nutritional therapy. Curr Opin Clin Nutr Metab Care. 2008;11:452–458. doi: 10.1097/MCO.0b013e3282fcec49.
    1. Casaer MP, Hermans G, Wilmer A, Van den Berghe G. Impact of early parenteral nutrition completing enteral nutrition in adult critically ill patients (EPaNIC trial): a study protocol and statistical analysis plan for a randomized controlled trial. Trials. 2011;12:21. doi: 10.1186/1745-6215-12-21.
    1. McLaughlin AM, Hardt J, Canavan JB, Donnelly MB. Determining the economic cost of ICU treatment: a prospective 'micro-costing' study. Intensive Care Med. 2009;35:2135–2140. doi: 10.1007/s00134-009-1622-1.
    1. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313:275–283. doi: 10.1136/bmj.313.7052.275.
    1. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. Am J Respir Crit Care Med. 2002;165:540–550.
    1. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8:521–533. doi: 10.1111/j.1524-4733.2005.00045.x.
    1. Belgian Health Care Knowledge Centre (KCE) reports 78A 2008.
    1. Barber JA, Thompson SG. Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ. 1998;317:1195–1200. doi: 10.1136/bmj.317.7167.1195.
    1. Coughlin MT, Angus DC. Economic evaluation of new therapies in critical illness. Crit Care Med. 2003;31:S7–16. doi: 10.1097/00003246-200301001-00002.
    1. Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health. 2009;6:2950–2966. doi: 10.3390/ijerph6122950.
    1. Vrijens F, Hulstaert F, Devriese S, van de Sande S. Hospital-acquired infections in Belgian acute-care hospitals: an estimation of their global impact on mortality, length of stay and healthcare costs. Epidemiol Infect. 2012;140:126–136. doi: 10.1017/S0950268811000100.
    1. Burgmann H, Hiesmayr JM, Savey A, Bauer P, Metnitz B, Metnitz PG. Impact of nosocomial infections on clinical outcome and resource consumption in critically ill patients. Intensive Care Med. 2010;36:1597–1601. doi: 10.1007/s00134-010-1941-2.
    1. Higgins TL, McGee WT, Steingrub JS, Rapoport J, Lemeshow S, Teres D. Early indicators of prolonged intensive care unit stay: impact of illness severity, physician staffing, and pre-intensive care unit length of stay. Crit Care Med. 2003;31:45–51. doi: 10.1097/00003246-200301000-00007.
    1. Wilkinson L. Revising the Pareto chart. The American Statistician. 2006;60:332–334. doi: 10.1198/000313006X152243.
    1. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index 2012.
    1. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320:1197–1200. doi: 10.1136/bmj.320.7243.1197.
    1. DSS Research homepage.
    1. Van den Berghe G, Wouters PJ, Kesteloot K, Hilleman DE. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med. 2006;34:612–616.
    1. Krinsley JS, Jones RL. Cost analysis of intensive glycemic control in critically ill adult patients. Chest. 2006;129:644–650. doi: 10.1378/chest.129.3.644.
    1. Sadhu AR, Ang AC, Ingram-Drake LA, Martinez DS, Hsueh WA, Ettner SL. Economic benefits of intensive insulin therapy in critically Ill patients: the targeted insulin therapy to improve hospital outcomes (TRIUMPH) project. Diabetes Care. 2008;31:1556–1561. doi: 10.2337/dc07-2456.
    1. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31:1–11. doi: 10.1097/00003246-200301000-00001.
    1. Nilsson G, Hojgard S, Berntorp E. Treatment of the critically ill patient with protein C: is it worth the cost? Thromb Res. 2010;125:494–500. doi: 10.1016/j.thromres.2009.09.008.
    1. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care. 2005;43:5–14.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren